Skip to main content

Table 4 Adverse events while taking sirolimus according to the duration of treatment in patients with LAM

From: Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis

Time after sirolimus (years) Number (%)
Year 1 (N = 107) Year 2 (N = 70) Year 3 (N = 53) Year 4 (N = 30)
Mouth ulcer 73 (68.2) 33 (47.1) 22 (41.5) 7 (23.3)
Menstrual abnormality 62 (57.9) 34 (48.6) 16 (30.2) 8 (26.7)
Acne 37 (34.6) 22 (31.4) 12 (22.6) 3 (10.0)
Ovarian cystsa 17/55 (30.9) 10/37 (27.0) 6/25 (24.0) 1/8 (12.5)
Weakness 11 (10) 1 (1.4) 0 0
Peripheral edema 6 (5.6) 2 (2.9) 1 (1.9) 1 (3.3)
Diarrhea 6 (5.6) 1 (1.4) 0 0
Rash 5 (4.7) 0 0 1 (3.3)
Nausea 5 (4.7) 0 1 (1.9) 0
Weight loss 5 (4.7) 0 0 0
Arthralgia 4 (3.7) 0 0 1 (3.3)
Abdominal pain 3 (2.8) 2 (2.9) 0 0
Pruritus 3 (2.8) 1 (1.4) 0 0
Abdominal distention 2 (1.9) 0 0 0
Fever 2 (1.9) 0 0 0
Chest pain 2 (1.9) 1 (1.4) 1 (1.9) 1 (3.3)
Toothache 1 (0.9) 0 0 0
Gingival hyperplasia 1 (0.9) 0 0 0
Periodontitis 1 (0.9) 0 0 0
Herpes zoster 1 (0.9) 1 (1.4) 0 0
Alopecia 1 (0.9) 0 0 0
Headache 1 (0.9) 0 0 0
Dizziness 1 (0.9) 0 0 0
Palpitation 1 (0.9) 0 0 0
Myalgia 1 (0.9) 0 0 0
Tenosynovitis 1 (0.9) 0 0 0
  1. abased on patients evaluated